Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY 株式レポート

時価総額：US$35.3b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Alnylam Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Alnylam Pharmaceuticals'の CEO はYvonne Greenstreetで、 Jan2022年に任命され、 の在任期間は 2.42年です。 の年間総報酬は$ 8.90Mで、 11%給与と89%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.038%を直接所有しており、その価値は$ 7.63M 。経営陣と取締役会の平均在任期間はそれぞれ2.9年と8.6年です。

主要情報

Yvonne Greenstreet

最高経営責任者

US$8.9m

報酬総額

CEO給与比率11.0%
CEO在任期間2.7yrs
CEOの所有権0.04%
経営陣の平均在職期間3.2yrs
取締役会の平均在任期間8.8yrs

経営陣の近況

Recent updates

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04
Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02
Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Oct 07

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Sep 26

Alnylam RNAi therapy for rare protein disorder gets EU approval

Sep 20

Alnylam to offer $900M convertible senior notes

Sep 12

CEO報酬分析

Alnylam Pharmaceuticals の収益と比較して、Yvonne Greenstreet の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$332m

Dec 31 2023US$9mUS$976k

-US$440m

Sep 30 2023n/an/a

-US$510m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$5mUS$850k

-US$1b

Sep 30 2022n/an/a

-US$1b

Jun 30 2022n/an/a

-US$981m

Mar 31 2022n/an/a

-US$893m

Dec 31 2021US$9mUS$619k

-US$853m

Sep 30 2021n/an/a

-US$838m

Jun 30 2021n/an/a

-US$887m

Mar 31 2021n/an/a

-US$876m

Dec 31 2020US$3mUS$622k

-US$858m

Sep 30 2020n/an/a

-US$891m

Jun 30 2020n/an/a

-US$846m

Mar 31 2020n/an/a

-US$886m

Dec 31 2019US$3mUS$571k

-US$886m

Sep 30 2019n/an/a

-US$821m

Jun 30 2019n/an/a

-US$858m

Mar 31 2019n/an/a

-US$802m

Dec 31 2018US$3mUS$540k

-US$761m

Sep 30 2018n/an/a

-US$692m

Jun 30 2018n/an/a

-US$570m

Mar 31 2018n/an/a

-US$525m

Dec 31 2017US$985kUS$504k

-US$491m

報酬と市場: Yvonneの 総報酬 ($USD 8.90M ) は、 US市場 ($USD 13.52M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Yvonneの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Yvonne Greenstreet (61 yo)

2.7yrs

在職期間

US$8,895,670

報酬

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Yvonne Greenstreet
CEO & Director2.7yrsUS$8.90m0.039%
$ 13.8m
Jeffrey Poulton
CFO & Executive VP5.1yrsUS$3.22m0.017%
$ 5.8m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardless than a yearUS$3.32m0.018%
$ 6.4m
Pushkal Garg
Chief Medical Officer9.9yrsUS$3.23m0.0090%
$ 3.2m
Tolga Tanguler
Executive VP & Chief Commercial Officer3.7yrsUS$2.87m0.0054%
$ 1.9m
Timothy Maines
Chief Technical Operations & Quality Officer1.7yrsデータなしデータなし
Kevin Fitzgerald
Senior VP5.3yrsデータなし0.010%
$ 3.7m
Christine Lindenboom
Senior VP of Investor Relations & Corporate Communicationsno dataデータなしデータなし
Piyush Sharma
Chief Ethics & Compliance Officer2yrsデータなしデータなし
Evan Lippman
Chief Corporate Development & Strategy Officer2yrsデータなしデータなし
Kelley Boucher
Chief Human Resource Officer5.3yrsデータなしデータなし
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Boardno dataデータなしデータなし

3.2yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: ALNYの経営陣は 経験豊富 であると考えられます ( 2.9年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Yvonne Greenstreet
CEO & Director2.9yrsUS$8.90m0.039%
$ 13.8m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardno dataUS$3.32m0.018%
$ 6.4m
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board8.9yrsデータなしデータなし
Peter Kellogg
Independent Director1.5yrsUS$658.72k0%
$ 0
Paul Schimmel
Member of the Scientific Advisory Boardno dataUS$516.04kデータなし
David E. Pyott
Independent Director8.8yrsUS$477.21k0.022%
$ 7.7m
Phillip Sharp
Co-Founder22.3yrsUS$502.21k0.21%
$ 73.4m
Amy W. Schulman
Independent Chair of the Board & Lead Independent Director10.2yrsUS$531.36k0.0066%
$ 2.3m
Markus Stoffel
Member of Scientific Advisory Boardno dataデータなしデータなし
David Bartel
Member of Scientific Advisory Boardno dataデータなしデータなし
Dennis Ausiello
Member of the Scientific Advisory Board & Independent Director12.4yrsUS$477.21k0.0028%
$ 998.8k
Colleen Reitan
Independent Director6.3yrsUS$489.15k0%
$ 0

8.8yrs

平均在職期間

69.5yo

平均年齢

経験豊富なボード: ALNYの 取締役会 は 経験豊富 であると考えられます ( 8.6年の平均在任期間)。